Selenium is an essential element that is specifically incorporated as selenocystein into selenoproteins. It is a potent modulator of eukaryotic cell growth with strictly concentration-dependant effects. Lower concentrations are necessary for cell survival and growth, whereas higher concentrations inhibit growth and induce cell death. It is well established that selenium has cancer preventive effects, and several studies also have shown that it has strong anticancer effects with a selective cytotoxicity on malignant drug-resistant cells while only exerting marginal effects on normal and benign cells. This cancer-specific cytotoxicity is likely explained by high affinity selenium uptake dependent on proteins connected to multidrug resistance. One of the most studied selenoproteins in cancer is thioredoxin reductase (TrxR) that has important functions in neoplastic growth and is an important component of the resistant phenotype. Several reports have shown that TrxR is induced in tumor cells and pre-neoplastic cells, and several commonly used drugs interact with the protein. In this review, we summarize the current knowledge of selenium as a potent preventive and tumor selective anticancer drug, and we also discuss the potential of using the expression and modulation of the selenoprotein TrxR in the diagnostics and treatment of cancer. Antioxid. Redox Signal. 12, 867–880.
Get full access to this article
View all access options for this article.
References
1.
ArnerES, HolmgrenA. The thioredoxin system in cancer. Semin Cancer Biol, 16:420–426. 2006.
2.
ArnérES, NakamuraH, SasadaT, YodoiJ, HolmgrenA, SpyrouG. Analysis of the inhibition of mammalian thioredoxin, thioredoxin reductase, and glutaredoxin by cis-diamminedichloroplatinum (II) and its major metabolite, the glutathione-platinum complex. Free Radic Biol Med, 31:1170–1178. 2001.
3.
AssmannA, BrivibaK, SiesH. Reduction of methionine selenoxide to selenomethionine by glutathione. Arch Biochem Biophys, 349:201–203. 1998.
4.
BavnerA, MatthewsJ, SanyalS, GustafssonJA, TreuterE. EID3 is a novel EID family member and an inhibitor of CBP-dependent co-activation. Nucleic Acids Res, 33:3561–3569. 2005.
5.
BeckerK, GromerS, SchirmerRH, MullerS. Thioredoxin reductase as a pathophysiological factor and drug target. Eur J Biochem, 267:6118–6125. 2000.
6.
BeckerK, Herold–MendeC, ParkJJ, LoweG, SchirmerRH. Human thioredoxin reductase is efficiently inhibited by (2,2′:6′,2′′-terpyridine)platinum(II) complexes. Possible implications for a novel antitumor strategy. J Med Chem, 44:2784–2792. 2001.
7.
BeilsteinMA, WhangerPD. Chemical forms of selenium in rat tissues after administration of selenite or selenomethionine. J Nutr, 116:1711–1719. 1986.
8.
BerggrenM, GallegosA, GasdaskaJR, GasdaskaPY, WarnekeJ, PowisG. Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia. Anticancer Res, 16:3459–3466. 1996.
9.
BiaglowJE, MillerRA. The thioredoxin reductase/thioredoxin system: Novel redox targets for cancer therapy. Cancer Biol Ther, 4:6–13. 2005.
10.
BjelakovicG, NikolovaD, SimonettiRG, GluudC. Antioxidant supplements for prevention of gastrointestinal cancers: A systematic review and meta-analysis. Lancet, 364:1219–1228. 2004.
11.
Björkhem–BergmanL, JonssonK, ErikssonLC, OlssonJM, LehmannS, PaulC, BjornstedtM. Drug-resistant human lung cancer cells are more sensitive to selenium cytotoxicity. Effects on thioredoxin reductase and glutathione reductase. Biochem Pharmacol, 63:1875–1884. 2002.
12.
Björkhem–BergmanL, TorndalUB, EkenS, NystromC, CapitanioA, LarsenEH, BjornstedtM, ErikssonLC. Selenium prevents tumor development in a rat model for chemical carcinogenesis. Carcinogenesis, 26:125–131. 2005.
13.
Björkhem–BergmanL, TorndalUB, EkenS, NyströmC, CapitanioA, LarsenEH, BjörnstedtM, ErikssonLC. Selenium prevents tumor development in a rat model for chemical carcinogenesis. Carcinogenesis, 26:125–131. 2005.
14.
BjörkhemL, TeclebrhanH, KesenE, OlssonJM, ErikssonLC, BjornstedtM. Increased levels of cytosolic thioredoxin reductase activity and mRNA in rat liver nodules. J Hepatol, 35:259–264. 2001.
15.
BjörnstedtM, HambergM, KumarS, XueJ, HolmgrenA. Human thioredoxin reductase directly reduces lipid hydroperoxides by NADPH and selenocystine strongly stimulates the reaction via catalytically generated selenols. J Biol Chem, 270:11761–11764. 1995.
16.
BjörnstedtM, KumarS, BjorkhemL, SpyrouG, HolmgrenA. Selenium and the thioredoxin and glutaredoxin systems. Biomed Environ Sci, 10:271–279. 1997.
17.
BjörnstedtM, KumarS, HolmgrenA. Selenodiglutathione is a highly efficient oxidant of reduced thioredoxin and a substrate for mammalian thioredoxin reductase. J Biol Chem, 267:8030–8034. 1992.
18.
BjörnstedtM, KumarS, HolmgrenA. Selenite and selenodiglutathione: reactions with thioredoxin systems. Methods Enzymol, 252:209–219. 1995.
19.
BjörnstedtM, OdlanderB, KuprinS, ClaessonHE, HolmgrenA. Selenite incubated with NADPH and mammalian thioredoxin reductase yields selenide, which inhibits lipoxygenase and changes the electron spin resonance spectrum of the active site iron. Biochemistry, 35:8511–8516. 1996.
20.
BrinkmanBM. Splice variants as cancer biomarkers. Clin Biochem, 37:584–594. 2004.
21.
BrunsF, BuntzelJ, MuckeR, SchonekaesK, KistersK, MickeO. Selenium in the treatment of head and neck lymphedema. Med Princ Pract, 13:185–190. 2004.
22.
ButlerJA, BeilsteinMA, WhangerPD. Influence of dietary methionine on the metabolism of selenomethionine in rats. J Nutr, 119:1001–1009. 1989.
23.
CaffreyPB, ZhuM, FrenkelGD. Prevention of the development of melphalan resistance in vitro by selenite. Biol Trace Elem Res, 65:187–195. 1998.
24.
CavalieriRR, ScottKG, SairenjiE. Selenite (75Se) as a tumor-localizing agent in man. J Nucl Med, 7:197–208. 1966.
25.
ChungYW, KimTS, LeeSY, LeeSH, ChoiY, KimN, MinBM, JeongDW, KimIY. Selenite-induced apoptosis of osteoclasts mediated by the mitochondrial pathway. Toxicol Lett, 160:143–1-50. 2006.
26.
ClarkLC, CombsGFJr., TurnbullBW, SlateEH, ChalkerDK, ChowJ, DavisLS, GloverRA, GrahamGF, GrossEG, KrongradA, LesherJLJr., ParkHK, SandersBBJr., SmithCL, TaylorJR. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA, 276:1957–1963. 1996.
CunneaP, FernandesAP, CapitanioA, EkenS, SpyrouG, BjörnstedtM. Increased expression of specific thioredoxin family proteins; A pilot immunohistochemical study on human hepatocellular carcinoma. Int J Immunopathol Pharmacol, 20:17–24. 2007.
29.
Duffield–LillicoAJ, DalkinBL, ReidME, TurnbullBW, SlateEH, JacobsET, MarshallJR, ClarkLC. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: An analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int, 91:608–612. 2003.
30.
EstrelaJM, OrtegaA, ObradorE. Glutathione in cancer biology and therapy. Crit Rev Clin Lab Sci, 43:143–181. 2006.
31.
FanTW, HigashiRM, LaneAN. Integrating metabolomics and transcriptomics for probing SE anticancer mechanisms. Drug Metab Rev, 38:707–732. 2006.
32.
FedericoA, IodiceP, FedericoP, Del RioA, MelloneMC, CatalanoG. Effects of selenium and zinc supplementation on nutritional status in patients with cancer of digestive tract. Eur J Clin Nutr, 55:293–297. 2001.
33.
FernandesAP, CapitanioA, SeleniusM, BrodinO, RundlofAK, BjornstedtM. Expression profiles of thioredoxin family proteins in human lung cancer tissue: Correlation with proliferation and differentiation. Histopathology, 55:313–320. 2009.
34.
FialaES, StaretzME, PandyaGA, El–BayoumyK, HamiltonSR. Inhibition of DNA cytosine methyltransferase by chemopreventive selenium compounds, determined by an improved assay for DNA cytosine methyltransferase and DNA cytosine methylation. Carcinogenesis, 19:597–604. 1998.
35.
GanL, YangXL, LiuQ, XuHB. Inhibitory effects of thioredoxin reductase antisense RNA on the growth of human hepatocellular carcinoma cells. J Cell Biochem, 96:653–664. 2005.
36.
GandinV, NystromC, RundlöfAK, Jonsson–VidesaterK, SchonlauF, HorkkoJ, BjörnstedtM, FernandesAP. Effects of the antioxidant Pycnogenol on cellular redox systems in U1285 human lung carcinoma cells. FEBS J, 276:532–540. 2009.
37.
GantherHE. Reduction of the selenotrisulfide derivative of glutathione to a persulfide analog by glutathione reductase. Biochemistry, 10:4089–4098. 1971.
38.
GantherHE, CorcoranC. Selenotrisulfides. II. Cross-linking of reduced pancreatic ribonuclease with selenium. Biochemistry, 8:2557–2563. 1969.
39.
GasdaskaJR, GasdaskaPY, GallegosA, PowisG. Human thioredoxin reductase gene localization to chromosomal position 12q23-q24.1 and mRNA distribution in human tissue. Genomics, 37:257–259. 1996.
40.
GhignaC, ValaccaC, BiamontiG. Alternative splicing and tumor progression. Curr Genomics, 9:556–570. 2008.
41.
GladyshevVN, FactorVM, HousseauF, HatfieldDL. Contrasting patterns of regulation of the antioxidant selenoproteins, thioredoxin reductase, and glutathione peroxidase, in cancer cells. Biochem Biophys Res Commun, 251:488–493. 1998.
42.
GromerS, ArscottLD, WilliamsCHJr., SchirmerRH, BeckerK. Human placenta thioredoxin reductase. Isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds. J Biol Chem, 273:20096–20101. 1998.
43.
GromerS, SchirmerRH, BeckerK. The 58 kDa mouse selenoprotein is a BCNU-sensitive thioredoxin reductase. FEBS Lett, 412:318–320. 1997.
44.
GromerS, UrigS, BeckerK. The thioredoxin system—From science to clinic. Med Res Rev, 24:40–89. 2004.
45.
HaapasaloH, KylaniemiM, PaunulN, KinnulaVL, SoiniY. Expression of antioxidant enzymes in astrocytic brain tumors. Brain Pathol, 13:155–164. 2003.
46.
HashemySI, UngerstedtJS, Zahedi AvvalF, HolmgrenA. Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase. J Biol Chem, 281:10691–10697. 2006.
47.
HeC, ZhouF, ZuoZ, ChengH, ZhouR. A global view of cancer-specific transcript variants by subtractive transcriptome-wide analysis. PLoS ONE, 4:e4732. 2009.
HintzeKJ, WaldKA, ZengH, JefferyEH, FinleyJW. Thioredoxin reductase in human hepatoma cells is transcriptionally regulated by sulforaphane and other electrophiles via an antioxidant response element. J Nutr, 133:2721–2727. 2003.
50.
HuH, JiangC, SchusterT, LiGX, DanielPT, LuJ. Inorganic selenium sensitizes prostate cancer cells to TRAIL-induced apoptosis through superoxide/p53/Bax-mediated activation of mitochondrial pathway. Mol Cancer Ther, 5:1873–1882. 2006.
51.
HuYJ, ChenY, ZhangYQ, ZhouMZ, SongXM, ZhangBZ, LuoL, XuPM, ZhaoYN, ZhaoYB, ChengG. The protective role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients. Biol Trace Elem Res, 56:331–341. 1997.
52.
HuiL, ZhangX, WuX, LinZ, WangQ, LiY, HuG. Identification of alternatively spliced mRNA variants related to cancers by genome-wide ESTs alignment. Oncogene, 23:3013–3023. 2004.
53.
HusbeckB, BhattacharyyaRS, FeldmanD, KnoxSJ. Inhibition of androgen receptor signaling by selenite and methylseleninic acid in prostate cancer cells: Two distinct mechanisms of action. Mol Cancer Ther, 5:2078–2085. 2006.
54.
HusbeckB, NonnL, PeehlDM, KnoxSJ. Tumor-selective killing by selenite in patient-matched pairs of normal and malignant prostate cells. Prostate, 66:218–225. 2006.
55.
JarvelaS, BraggeH, PaunuN, JarvelaT, PaljarviL, KalimoH, HelenP, KinnulaV, SoiniY, HaapasaloH. Antioxidant enzymes in oligodendroglial brain tumors: association with proliferation, apoptotic activity and survival. J Neurooncol, 77:131–140. 2006.
56.
JiangC, WangZ, GantherH, LuJ. Distinct effects of methylseleninic acid versus selenite on apoptosis, cell cycle, and protein kinase pathways in DU145 human prostate cancer cells. Mol Cancer Ther, 1:1059–1066. 2002.
57.
JohnsonWD, MorrisseyRL, KapetanovicI, CrowellJA, McCormickDL. Subchronic oral toxicity studies of Se-methylselenocysteine, an organoselenium compound for breast cancer prevention. Food Chem Toxicol, 46:1068–1078. 2008.
58.
Jönsson–VidesaterK, Björkhem–BergmanL, HossainA, SoderbergA, ErikssonLC, PaulC, RosenA, BjörnstedtM. Selenite-induced apoptosis in doxorubicin-resistant cells and effects on the thioredoxin system. Biochem Pharmacol, 67:513–522. 2004.
59.
KahlosK, SoiniY, SailyM, KoistinenP, KakkoS, PaakkoP, HolmgrenA, KinnulaVL. Up-regulation of thioredoxin and thioredoxin reductase in human malignant pleural mesothelioma. Int J Cancer, 95:198–204. 2001.
60.
KanZ, Garrett–EngelePW, JohnsonJM, CastleJC. Evolutionarily conserved and diverged alternative splicing events show different expression and functional profiles. Nucleic Acids Res, 33:5659–5666. 2005.
61.
KasserollerR. Sodium selenite as prophylaxis against erysipelas in secondary lymphedema. Anticancer Res, 18:2227–2230. 1998.
62.
KimEH, SohnS, KwonHJ, KimSU, KimMJ, LeeSJ, ChoiKS. Sodium selenite induces superoxide-mediated mitochondrial damage and subsequent autophagic cell death in malignant glioma cells. Cancer Res, 67:6314–6324. 2007.
63.
KimIY, StadtmanTC. Inhibition of NF-kappaB DNA binding and nitric oxide induction in human T cells and lung adenocarcinoma cells by selenite treatment. Proc Natl Acad Sci USA, 94:12904–12907. 1997.
64.
KimT, JungU, ChoDY, ChungAS. Se-methylselenocysteine induces apoptosis through caspase activation in HL-60 cells. Carcinogenesis, 22:559–565. 2001.
65.
KimTS, YunBY, KimIY. Induction of the mitochondrial permeability transition by selenium compounds mediated by oxidation of the protein thiol groups and generation of the superoxide. Biochem Pharmacol, 66:2301–2311. 2003.
66.
Kiremidjian–SchumacherL, RoyM. Effect of selenium on the immunocompetence of patients with head and neck cancer and on adoptive immunotherapy of early and established lesions. Biofactors, 14:161–168. 2001.
67.
Kiremidjian–SchumacherL, StotzkyG. Selenium and immune responses. Environ Res, 42:277–303. 1987.
68.
KumarS, BjörnstedtM, HolmgrenA. Selenite is a substrate for calf thymus thioredoxin reductase and thioredoxin and elicits a large non-stoichiometric oxidation of NADPH in the presence of oxygen. Eur J Biochem, 207:435–439. 1992.
69.
LanfearJ, FlemingJ, WuL, WebsterG, HarrisonPR. The selenium metabolite selenodiglutathione induces p53 and apoptosis: relevance to the chemopreventive effects of selenium?Carcinogenesis, 15:1387–1392. 1994.
70.
LarsenEH, HansenM, PaulinH, MoesgaardS, ReidM, RaymanM. Speciation and bioavailability of selenium in yeast-based intervention agents used in cancer chemoprevention studies. J AOAC Int, 87:225–232. 2004.
71.
LeDT, LiangX, FomenkoDE, RazaAS, ChongCK, CarlsonBA, HatfieldDL, GladyshevVN. Analysis of methionine/selenomethionine oxidation and methionine sulfoxide reductase function using methionine-rich proteins and antibodies against their oxidized forms. Biochemistry, 47:6685–6694. 2008.
72.
LeeJT, LeeTJ, ParkJW, KwonTK. Se-methylselenocysteine sensitized TRAIL-mediated apoptosis via down-regulation of Bcl-2 expression. Int J Oncol, 34:1455–1460. 2009.
73.
LiGX, HuH, JiangC, SchusterT, LuJ. Differential involvement of reactive oxygen species in apoptosis induced by two classes of selenium compounds in human prostate cancer cells. Int J Cancer, 120:2034–2043. 2007.
74.
LinS, CullenWR, ThomasDJ. Methylarsenicals and arsinothiols are potent inhibitors of mouse liver thioredoxin reductase. Chem Res Toxicol, 12:924–930. 1999.
75.
LinS, Del RazoLM, StybloM, WangC, CullenWR, ThomasDJ. Arsenicals inhibit thioredoxin reductase in cultured rat hepatocytes. Chem Res Toxicol, 14:305–311. 2001.
76.
LincolnDT, Ali EmadiEM, TonissenKF, ClarkeFM. The thioredoxin-thioredoxin reductase system: over-expression in human cancer. Anticancer Res, 23:2425–2433. 2003.
77.
LippmanSM, KleinEA, GoodmanPJ, LuciaMS, ThompsonIM, FordLG, ParnesHL, MinasianLM, GazianoJM, HartlineJA, ParsonsJK, BeardenJD3rd, CrawfordED, GoodmanGE, ClaudioJ, WinquistE, CookED, KarpDD, WaltherP, LieberMM, KristalAR, DarkeAK, ArnoldKB, GanzPA, SantellaRM, AlbanesD, TaylorPR, ProbstfieldJL, JagpalTJ, CrowleyJJ, MeyskensFLJr., BakerLH, ColtmanCAJr.Effect of selenium and vitamin E on risk of prostate cancer and other cancers: The Selenium and Vitamin E Cancer Prevention Trial (SELECT)JAMA, 301:39–51. 2009.
78.
LiuJ, AkahoshiT, NamaiR, MatsuiT, KondoH. Effect of auranofin, an antirheumatic drug, on neutrophil apoptosis. Inflamm Res, 49:445–451. 2000.
79.
LuJ, ChewEH, HolmgrenA. Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc Natl Acad Sci USA, 104:12288–12293. 2007.
80.
MadejaZ, SrokaJ, NystromC, Björkhem–BergmanL, NordmanT, DamdimopoulosA, NalvarteI, ErikssonLC, SpyrouG, OlssonJM, BjörnstedtM. The role of thioredoxin reductase activity in selenium-induced cytotoxicity. Biochem Pharmacol, 69:1765–1772. 2005.
81.
MarzanoC, GandinV, FoldaA, ScutariG, BindoliA, RigobelloMP. Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. Free Radic Biol Med, 42:872–881. 2007.
82.
MauBL, PowisG. Inhibition of thioredoxin reductase (E.C. 1.6.4.5.) by antitumor quinones. Free Radic Res Commun, 8:365–372. 1990.
83.
McKeehanWL, HamiltonWG, HamRG. Selenium is an essential trace nutrient for growth of WI-38 diploid human fibroblasts. Proc Natl Acad Sci USA, 73:2023–2027. 1976.
84.
MickeO, BrunsF, MuckeR, SchaferU, GlatzelM, DeVriesAF, SchonekaesK, KistersK, BuntzelJ. Selenium in the treatment of radiation-associated secondary lymphedema. Int J Radiat Oncol Biol Phys, 56:40–49. 2003.
85.
MoosPJ, EdesK, CassidyP, MassudaE, FitzpatrickFA. Electrophilic prostaglandins and lipid aldehydes repress redox-sensitive transcription factors p53 and hypoxia-inducible factor by impairing the selenoprotein thioredoxin reductase. J Biol Chem, 278:745–750. 2003.
86.
NadimintyN, GaoAC. Mechanisms of selenium chemoprevention and therapy in prostate cancer. Mol Nutr Food Res, 52:1247–1260. 2008.
87.
NguyenP, AwwadRT, SmartDD, SpitzDR, GiusD. Thioredoxin reductase as a novel molecular target for cancer therapy. Cancer Lett, 236:164–174. 2006.
88.
NilsonneG, OlmE, SzulkinA, MundtF, SteinA, KocicB, RundlofAK, FernandesAP, BjornstedtM, DobraK. Phenotype-dependent apoptosis signalling in mesothelioma cells after selenite exposure. J Exp Clin Cancer Res, 28:92. 2009.
NobelCS, BurgessDH, ZhivotovskyB, BurkittMJ, OrreniusS, SlaterAF. Mechanism of dithiocarbamate inhibition of apoptosis: thiol oxidation by dithiocarbamate disulfides directly inhibits processing of the caspase-3 proenzyme. Chem Res Toxicol, 10:636–643. 1997.
91.
NodaN, OchiaiA, Miyazaki, SugimuraT, TeradaM, WakasugiH. Detection of thioredoxin in gastric cancer: association with histological type. Antioxid Redox Signal, 2:519–528. 2000.
92.
OhtaY, SuzukiKT. Methylation and demethylation of intermediates selenide and methylselenol in the metabolism of selenium. Toxicol Appl Pharmacol, 226:169–177. 2008.
93.
OlmE, FernandesAP, HebertC, RundlofAK, LarsenEH, DanielssonO, BjornstedtM. Extracellular thiol-assisted selenium uptake dependent on the x(c)- cystine transporter explains the cancer-specific cytotoxicity of selenite. Proc Natl Acad Sci USA, 106:11400–11405. 2009.
94.
OlmE, Jonsson–VidesaterK, Ribera-CortadaI, FernandesAP, ErikssonLC, LehmannS, RundlöfAK, PaulC, BjörnstedtM. Selenite is a potent cytotoxic agent for human primary AML cells. Cancer Lett, 282:116–123. 2009.
95.
OmataY, FolanM, ShawM, MesserRL, LockwoodPE, HobbsD, BouillaguetS, SanoH, LewisJB, WatahaJC. Sublethal concentrations of diverse gold compounds inhibit mammalian cytosolic thioredoxin reductase (TrxR1)Toxicol In Vitro, 20:882–990. 2006.
96.
OsborneS, TonissenK. Genomic organisation and alternative splicing of mouse and human thioredoxin reductase 1 genes. BMC Genomics, 2:10. 2001.
97.
PagmantidisV, MeplanC, van SchothorstEM, KeijerJ, HeskethJE. Supplementation of healthy volunteers with nutritionally relevant amounts of selenium increases the expression of lymphocyte protein biosynthesis genes. Am J Clin Nutr, 87:181–189. 2008.
98.
PainterEP. The chemistry and toxicity of selenium compounds, with special reference to the selenium problem. Chem Rev, 28:179–213. 1941.
99.
PajaresMJ, EzpondaT, CatenaR, CalvoA, PioR, MontuengaLM. Alternative splicing: An emerging topic in molecular and clinical oncology. Lancet Oncol, 8:349–357. 2007.
100.
PakdamanA. Symptomatic treatment of brain tumor patients with sodium selenite, oxygen, and other supportive measures. Biol Trace Elem Res, 62:1–6. 1998.
101.
PappLV, LuJ, HolmgrenA, KhannaKK. From selenium to selenoproteins: Synthesis, identity, and their role in human health. Antioxid Redox Signal, 9:775–806. 2007.
ParkHS, ParkE, KimMS, AhnK, KimIY, ChoiEJ. Selenite inhibits the c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) through a thiol redox mechanism. J Biol Chem, 275:2527–2531. 2000.
104.
PowisG, KirkpatrickDL. Thioredoxin signaling as a target for cancer therapy. Curr Opin Pharmacol, 7:392–397. 2007.
105.
PowisG, MustacichD, CoonA. The role of the redox protein thioredoxin in cell growth and cancer. Free Radic Biol Med, 29:312–322. 2000.
106.
Ravn–HarenG, KrathBN, OvervadK, ColdS, MoesgaardS, LarsenEH, DragstedLO. Effect of long-term selenium yeast intervention on activity and gene expression of antioxidant and xenobiotic metabolising enzymes in healthy elderly volunteers from the Danish Prevention of Cancer by Intervention by Selenium (PRECISE) pilot study. Br J Nutr, 99:1190–1198. 2008.
107.
RaymanMP. Selenoproteins and human health: Insights from epidemiological data. Biochim Biophys Acta, 1790:1533–1540. 2009.
108.
ReidME, StrattonMS, LillicoAJ, FakihM, NatarajanR, ClarkLC, MarshallJR. A report of high-dose selenium supplementation: Response and toxicities. J Trace Elem Med Biol, 18:69–74. 2004.
109.
RenX, BjörnstedtM, ShenB, EricsonML, HolmgrenA. Mutagenesis of structural half-cystine residues in human thioredoxin and effects on the regulation of activity by selenodiglutathione. Biochemistry, 32:9701–9708. 1993.
110.
RigobelloMP, GandinV, FoldaA, RundlöfAK, FernandesAP, BindoliA, MarzanoC, BjörnstedtM. Treatment of human cancer cells with selenite or tellurite in combination with auranofin enhances cell death due to redox shift. Free Radic Biol Med, 47:710–721. 2009.
111.
RigobelloMP, ScutariG, FoldaA, BindoliA. Mitochondrial thioredoxin reductase inhibition by gold(I) compounds and concurrent stimulation of permeability transition and release of cytochrome c. Biochem Pharmacol, 67:689–696. 2004.
112.
RudolfE, RudolfK, CervinkaM. Selenium activates p53 and p38 pathways and induces caspase-independent cell death in cervical cancer cells. Cell Biol Toxicol, 24:123–141. 2008.
113.
RundlofAK, CarlstenM, ArnerES. The core promoter of human thioredoxin reductase 1: Cloning, transcriptional activity, and Oct-1, Sp1, and Sp3 binding reveal a housekeeping-type promoter for the AU-rich element-regulated gene. J Biol Chem, 276:30542–30551. 2001.
114.
RundlofAK, JanardM, Miranda–VizueteA, ArnerES. Evidence for intriguingly complex transcription of human thioredoxin reductase 1. Free Radic Biol Med, 36:641–656. 2004.
115.
RundlöfAK, FernandesAP, SeleniusM, BabicM, ShariatgorjiM, NilsonneG, IlagLL, DobraK, BjörnstedtM. Quantification of alternative mRNA species and identification of thioredoxin reductase 1 isoforms in human tumor cells. Differentiation, 75:123–132. 2007.
116.
SaitohM, NishitohH, FujiiM, TakedaK, TobiumeK, SawadaY, KawabataM, MiyazonoK, IchijoH. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J, 17:2596–2606. 1998.
117.
SakuraiA, NishimotoM, HimenoS, ImuraN, TsujimotoM, KunimotoM, HaraS. Transcriptional regulation of thioredoxin reductase 1 expression by cadmium in vascular endothelial cells: role of NF-E2-related factor-2. J Cell Physiol, 203:529–537. 2005.
118.
SchrauzerGN, WhiteDA, SchneiderCJ. Cancer mortality correlation studies–III: Statistical associations with dietary selenium intakes. Bioinorg Chem, 7:23–31. 1977.
119.
SchwiertzA, DeubelS, BirringerM. Bioactivation of selenocysteine derivatives by beta-lyases present in common gastrointestinal bacterial species. Int J Vitam Nutr Res, 78:169–174. 2008.
120.
SeleniusM, FernandesAP, BrodinO, BjörnstedtM, RundlöfAK. Treatment of lung cancer cells with cytotoxic levels of sodium selenite: Effects on the thioredoxin system. Biochem Pharmacol, 75:2092–2099. 2008.
121.
SeoYR, KelleyMR, SmithML. Selenomethionine regulation of p53 by a ref1-dependent redox mechanism. Proc Natl Acad Sci USA, 99:14548–14553. 2002.
122.
ShambergerRJ, WillisCE. Selenium distribution and human cancer mortality. CRC Crit Rev Clin Lab Sci, 2:211–221. 1971.
123.
ShenH, YangC, LiuJ, OngC. Dual role of glutathione in selenite-induced oxidative stress and apoptosis in human hepatoma cells. Free Radic Biol Med, 28:1115–1124. 2000.
124.
ShenHM, YangCF, DingWX, LiuJ, OngCN. Superoxide radical-initiated apoptotic signalling pathway in selenite-treated HepG(2) cells: mitochondria serve as the main target. Free Radic Biol Med, 30:9–21. 2001.
125.
ShenHM, YangCF, OngCN. Sodium selenite-induced oxidative stress and apoptosis in human hepatoma HepG2 cells. Int J Cancer, 81:820–828. 1999.
126.
ShihAY, JohnsonDA, WongG, KraftAD, JiangL, ErbH, JohnsonJA, MurphyTH. Coordinate regulation of glutathione biosynthesis and release by Nrf2-expressing glia potently protects neurons from oxidative stress. J Neurosci, 23:3394–3406. 2003.
127.
ShiloS, TiroshO. Selenite activates caspase-independent necrotic cell death in Jurkat T cells and J774.2 macrophages by affecting mitochondrial oxidant generation. Antioxid Redox Signal, 5:273–279. 2003.
128.
SiejaK, TalerczykM. Selenium as an element in the treatment of ovarian cancer in women receiving chemotherapy. Gynecol Oncol, 93:320–327. 2004.
129.
SoiniY, KahlosK, NapankangasU, Kaarteenaho-WiikR, SailyM, KoistinenP, PaaakkoP, HolmgrenA, KinnulaVL. Widespread expression of thioredoxin and thioredoxin reductase in non-small cell lung carcinoma. Clin Cancer Res, 7:1750–1757. 2001.
130.
SpallholzJE, ShriverBJ, ReidTW. Dimethyldiselenide and methylseleninic acid generate superoxide in an in vitro chemiluminescence assay in the presence of glutathione: implications for the anticarcinogenic activity of L-selenomethionine and L-Se-methylselenocysteine. Nutr Cancer, 40:34–41. 2001.
131.
SpyrouG, BjörnstedtM, KumarS, HolmgrenA. AP-1 DNA-binding activity is inhibited by selenite and selenodiglutathione. FEBS Lett, 368:59–63. 1995.
132.
SpyrouG, BjörnstedtM, SkogS, HolmgrenA. Selenite and selenate inhibit human lymphocyte growth via different mechanisms. Cancer Res, 56:4407–4412. 1996.
133.
SrebrowA, KornblihttAR. The connection between splicing and cancer. J Cell Sci, 119:2635–2641. 2006.
134.
StewartMS, SpallholzJE, NeldnerKH, PenceBC. Selenium compounds have disparate abilities to impose oxidative stress and induce apoptosis. Free Radic Biol Med, 26:42–48. 1999.
135.
SunX, DobraK, BjörnstedtM, HjerpeA. Upregulation of 9 genes, including that for thioredoxin, during epithelial differentiation of mesothelioma cells. Differentiation, 66:181–188. 2000.
136.
SuzukiKT, KurasakiK, SuzukiN. Selenocysteine beta-lyase and methylselenol demethylase in the metabolism of Se-methylated selenocompounds into selenide. Biochim Biophys Acta, 1770:1053–1061. 2007.
137.
TalbotS, NelsonR, SelfWT. Arsenic trioxide and auranofin inhibit selenoprotein synthesis: Implications for chemotherapy for acute promyelocytic leukaemia. Br J Pharmacol, 154:940–948. 2008.
138.
TarzeA, DauplaisM, GrigorasI, LazardM, Ha–DuongNT, BarbierF, BlanquetS, PlateauP. Extracellular production of hydrogen selenide accounts for thiol-assisted toxicity of selenite against Saccharomyces cerevisiae. J Biol Chem, 282:8759–8767. 2007.
139.
ThorsenK, SorensenKD, Brems–EskildsenAS, ModinC, GaustadnesM, HeinAM, KruhofferM, LaurbergS, BorreM, WangK, BrunakS, KrainerAR, TorringN, DyrskjotL, AndersenCL, OrntoftTF. Alternative splicing in colon, bladder, and prostate cancer identified by exon array analysis. Mol Cell Proteomics, 7:1214–1224. 2008.
140.
TsenCC, TappelAL. Catalytic oxidation of glutathione and other sulfhydryl compounds by selenite. J Biol Chem, 233:1230–1232. 1958.
141.
TsujiY, SuzukiN, KTS, OgraY. Selenium metabolism in rats with long-term ingestion of Se-methylselenocysteine using enriched stable isotopes. J Toxicol Sci, 34:191–200. 2009.
142.
UrigS, BeckerK. On the potential of thioredoxin reductase inhibitors for cancer therapy. Semin Cancer Biol, 16:452–465. 2006.
143.
WangL, BonordenMJ, LiGX, LeeHJ, HuH, ZhangY, LiaoJD, ClearyMP, LuJ. Methyl-selenium compounds inhibit prostate carcinogenesis in the transgenic adenocarcinoma of mouse prostate model with survival benefit. Cancer Prev Res (Phila Pa), 2:484–495. 2009.
WhangerPD. Selenium and its relationship to cancer: An update. Br J Nutr, 91:11–28. 2004.
150.
WillettWC, PolkBF, MorrisJS, StampferMJ, PresselS, RosnerB, TaylorJO, SchneiderK, HamesCG. Prediagnostic serum selenium and risk of cancer. Lancet, 2:130–134. 1983.
151.
WitteAB, AnestålK, JerremalmE, EhrssonH, ArnérES. Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds. Free Radic Biol Med, 39:696–703. 2005.
152.
XiaL, NordmanT, OlssonJM, DamdimopoulosA, Bjorkhem-BergmanL, NalvarteI, ErikssonLC, ArnerES, SpyrouG, BjornstedtM. The mammalian cytosolic selenoenzyme thioredoxin reductase reduces ubiquinone. A novel mechanism for defense against oxidative stress. J Biol Chem, 278:2141–2146. 2003.
153.
XuQ, LeeC. Discovery of novel splice forms and functional analysis of cancer-specific alternative splicing in human expressed sequences. Nucleic Acids Res, 31:5635–5643. 2003.
154.
YanL, SpallholzJE. Generation of reactive oxygen species from the reaction of selenium compounds with thiols and mammary tumor cells. Biochem Pharmacol, 45:429–437. 1993.
155.
YangG, ZhouR, YinS, GuL, YanB, LiuY, LiuY, LiX. Studies of safe maximal daily dietary selenium intake in a seleniferous area in China. I. Selenium intake and tissue selenium levels of the inhabitants. J Trace Elem Electrolytes Health Dis, 3:77–87. 1989.
YooMH, XuXM, CarlsonBA, PattersonAD, GladyshevVN, HatfieldDL. Targeting thioredoxin reductase 1 reduction in cancer cells inhibits self-sufficient growth and DNA replication. PLoS ONE, 2:e1112. 2007.
158.
ZhaoR, XiangN, DomannFE, ZhongW. Expression of p53 enhances selenite-induced superoxide production and apoptosis in human prostate cancer cells. Cancer Res, 66:2296–2304. 2006.
159.
ZimmermannT, LeonhardtH, KerstingS, AlbrechtS, RangeU, EckeltU. Reduction of postoperative lymphedema after oral tumor surgery with sodium selenite. Biol Trace Elem Res, 106:193–203. 2005.
